Association of Celiac Disease With Pembrolizumab

Immune checkpoint inhibitors (ICIs) in the recent times have transformed the landscape of the management of many solid tumors. Unfortunately, many immune-related adverse effects are associated with ICIs, which lead to a negative outcome in cancer treatment. We present a case of a 63-year-old female with metastatic adenocarcinoma of unknown origin, who developed celiac disease during the course of treatment with pembrolizumab. Association of celiac disease with this form of immunotherapy has never been documented before.

[1]  M. Mino‐Kenudson,et al.  Immune checkpoint inhibitor-associated celiac disease , 2020, Journal for immunotherapy of cancer.

[2]  D. Schadendorf,et al.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[5]  Tsung-Teh Wu,et al.  Association between ipilimumab and celiac disease. , 2013, Mayo Clinic proceedings.

[6]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Ronfani,et al.  Accuracy of Diagnostic Antibody Tests for Coeliac Disease in Children: Summary of an Evidence Report , 2012, Journal of pediatric gastroenterology and nutrition.

[8]  D. Schuppan,et al.  Celiac disease: from pathogenesis to novel therapies. , 2009, Gastroenterology.

[9]  L. Sollid,et al.  Tissue-mediated control of immunopathology in coeliac disease , 2009, Nature Reviews Immunology.

[10]  P. Green,et al.  Trends in the presentation of celiac disease. , 2006, The American journal of medicine.

[11]  P. Green.  The many faces of celiac disease: clinical presentation of celiac disease in the adult population. , 2005, Gastroenterology.

[12]  B. Creamer,et al.  Response to a gluten-free diet of patients with the coeliac syndrome. , 1967, Lancet.

[13]  R. Kefford,et al.  Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. , 2015, Journal of immunotherapy.

[14]  N. Bizzaro,et al.  Diagnostic efficacy of the ELISA test for the detection of deamidated anti‐gliadin peptide antibodies in the diagnosis and monitoring of celiac disease , 2009, Journal of clinical laboratory analysis.

[15]  K. Forde,et al.  Significance of unsuspected celiac disease detected at endoscopy. , 2000, Gastrointestinal endoscopy.